Open AccessUse of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.
Author(s) -
Giovanna Rivas,
Néstor Llinás,
Carlos Bonilla,
Juan Rubiano,
Javier Cuello,
Natalia Arango
Publication year - 2017
Publication title -
revista colombiana de hematología y oncología
Language(s) - English
Resource type - Journals
eISSN - 2256-2877
pISSN - 2256-2915
DOI - 10.51643/22562915.261
Subject(s) - medicine , erlotinib , pregnancy , asymptomatic , pediatrics , gestation , adenocarcinoma , lung , lung cancer , surgery , cancer , epidermal growth factor receptor , biology , genetics
The use of erlotinib throughout pregnancy has not been previously reported. We present the case of a 40 yearold female patient with stage IV lung adenocarcinoma, mediastinal, bone and cerebral metastasis, a EGFR mutation and no smoking history, who had begun first line treatment with erlotinib 150 mg once daily. After two and a half months of treatment a fourteen-week pregnancy was documented, and after informing on fetal risks secondary to erlotinib use and maternal risks secondary to treatment withholding, she decided to continue with treatment under clinical surveillance by both the oncology and obstetrics clinics. At thirty-three weeks gestation a live born 1600 g female was born by caesarean section without evidence of congenital malformations. Imaging assessment after eight months of treatment showed complete bone and central nervous system response and partial lung and mediastinal response. The patient is currently undergoing the 11th month of treatment and is asymptomatic, the baby is 4 months old and is in good health.